Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified various functional groups and chemical constituents in dried leaves of the medicinal plant Bhringaraj, suggesting their potential use in developing wastewater treatment technologies.

In this study, baricitinib, a JAK inhibitor, was found to significantly improve scalp hair regrowth in both adults and adolescents with severe alopecia areata, with many achieving nearly full regrowth by weeks 36 or 52.

In this study, researchers found that patients with severe alopecia areata show varied regrowth timelines with baricitinib, and those with the most severe cases may still experience delayed but eventual improvement.

In this study, herbal hair oils made from Cuscuta reflexa showed effectiveness in promoting hair growth, reducing dandruff, and minimizing hair fall when tested on human volunteers and rats.

In this study, baricitinib treatment for severe alopecia areata was associated with complete hair regrowth after 12 months in two patients, suggesting it may be an effective alternative to traditional therapies, although safety and clinical implications need careful consideration.

In this study, the researchers identified MJ04, a selective JAK3 inhibitor, as a promising candidate for promoting hair growth, demonstrating efficacy in both animal models and human hair follicle assays with a favorable safety and pharmacokinetic profile.

This study identified corilagin as a major antitumor component in Phyllanthus niruri, with broad-spectrum activity against cancer cells and high content in Dimocarpus longan.

This study in a real-world setting found that baricitinib was effectively reducing disease severity in severe alopecia areata patients over 52 weeks, with 37.20% of participants achieving significant improvement and 72.40% experiencing mild or no adverse events.

This study's market analysis suggests that a project to produce and market aloe vera lotion for hair loss in Morona is feasible, with significant unmet demand and a positive financial outlook.

This source reports that a network meta-analysis found oral baricitinib and ruxolitinib to be effective and safe for treating alopecia areata, significantly improving response rates over placebos and showing fewer adverse effects than steroid treatments, though precise dosing needs further study.

This review focuses on the significant pharmacological properties and therapeutic potential of phytosterols, terpenoids, flavonoids, and phenolic compounds from the endangered plant Nardostachys Jatamansi, highlighting their diverse applications in disease prevention and treatment.

This narrative review reports that Janus kinase inhibitors show promise as an effective treatment for alopecia areata, especially in patients who do not respond to conventional therapies, although further research on long-term use and topical application is needed.

This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.

In this study, combining baricitinib and prednisone effectively achieved complete hair regrowth in seven out of eight women with very severe alopecia areata, contrasting with less effective results from each drug used alone.

This review highlights various pharmacological activities of the herbal plant Hansraj (Adiantum capillus-veneris), including antioxidant, wound healing, anti-microbial, and anti-diabetic effects, but stresses the need for further research and clinical trials to confirm these potential benefits and safety concerns.

This study examined the formulation of an oil derived from Alkanna tinctoria roots, traditionally used for hair health, and discusses its potential benefits for controlling hair loss, baldness, and premature greying, while promoting hair growth.

Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.

This article discusses baricitinib, a JAK1 and JAK2 inhibitor, as an approved and promising treatment for alopecia areata but reports no new clinical results.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

This study found that jujube seed oil significantly increased the number of hair follicles in BALB/c mice compared to controls, suggesting potential benefits for hair growth.

In this study, a hair tonic formulation with bean leaf juice increased hair growth in male rabbits, with concentration-dependent improvements in hair length and weight compared to a control.

This source reports that JAK inhibitors, such as ruxolitinib, baricitinib, and tofacitinib, have led to hair regrowth in alopecia areata patients and animal models, but their long-term safety and effectiveness remain uncertain, with ongoing trials to further investigate these factors.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

In this case report, researchers documented the first instance of alopecia in a bat from Veracruz, México, specifically in an individual of Artibeus jamaicensis, likely caused by a thoracic injury leading to an infection.

This study conducted a survey among consultant dermatologists in Ireland to explore their use of JAK inhibitors for treating alopecia areata, acknowledging challenges posed by the lack of global guidelines and long-term safety data.

In this study, researchers formulated a hair gel using guar gum and jatamansi extract, evaluating its physical properties and noting that jatamansi may promote hair growth, with the gel meeting various parameters such as pH, viscosity, and spreadability.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

In this study, the hair tonic made from the ethanol extract of bandotan leaves, applied on local male rabbits for 21 days, demonstrated significant hair growth activity, especially at a 20% concentration, showing the highest hair length and weight improvements.

This clinical trial reported that Sandalore® 1% significantly reduced hair shedding and increased hair volume and anagen HFs in women with telogen effluvium compared to placebo, supporting its potential use in hair growth treatments.